Drug-Drug Interaction between Clopidogrel and Neobavaisoflavone, Corylifolinin, and Coryfolin

Clopidogrel, sold under the name Plavix by Sandi and Bristol-Myers Squibb, has been clinically utilized to inhibit blood clots in a variety of conditions such as peripheral vascular disease, coronary artery disease, and cerebrovascular disease. Fructus Psoraleae (bu-gu-zhi in China) has the therapeutic potential towards coronary artery disease. The present study aims to determine the inhibition of Fructus Psoraleae's compounds towards human carboxyl esterase 1 (CES1)-catalyzed metabolic inactivation pathway of clopidogrel. Neobavaisoflavone, corylifolinin, and coryfolin (100 FM) was utilized to screen the inhibition towards human liver microsomes (BILMs)-catalyzed hydrolysis metabolism of clopidogrel, and the results showed all the tested compounds exhibited significant inhibition towards hydrolysis metabolism of clopidogrel. Concentration -dependent inhibition behavior was furtherly found. Therefore, the co -administration of Fructus Psoraleae might increase the therapeutic function of clopidogrel through inhibiting the inactivation metabolic reaction of clopidogrel.